South Africa's Aspen Pharmacare would get a large manufacturing facility in France if it completes a deal to buy GlaxoSmithKline's older thrombosis drug brands, Arixtra and Fraxiparine. GlaxoSmithKline ($GSK) said today that Aspen has offered to acquire the product lines outside of China, India and Pakistan, where GSK intends to keep selling them. GSK owns 19% of Aspen, and the two have done deals like this for years. The plant in Notre-Dame-de-Bondeville has about 1,000 employees that would transfer to Aspen, according to Reuters. Terms of the proposed deal were not disclosed. If completed, GSK will pick up some cash for brands whose sales have been fading, and Aspen will further its aspiration to move into markets outside of its South African base. In February, Aspen said it intended to buy an API manufacturing plant in the Netherlands from Merck's MSD unit in Europe to feed its own moves into other parts of the world. Story | More